Latest Insider Transactions at Journey Medical Corp (DERM)
This section provides a real-time view of insider transactions for Journey Medical Corp (DERM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Journey Medical Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Journey Medical Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2023
|
Justin Adam Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,472
+27.7%
|
-
|
|
Jul 21
2023
|
Jeffrey Paley Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,472
+27.7%
|
-
|
|
Jul 21
2023
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,472
+27.7%
|
-
|
|
May 17
2023
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
24,377
-1.12%
|
$24,377
$1.34 P/Share
|
|
May 16
2023
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
20,000
-0.91%
|
$20,000
$1.25 P/Share
|
|
May 12
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
50,000
-1.28%
|
-
|
|
Feb 22
2023
|
Joseph Benesch CFO |
SELL
Open market or private sale
|
Direct |
2,768
-3.95%
|
$2,768
$1.97 P/Share
|
|
Feb 12
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
50,000
-1.26%
|
-
|
|
Nov 12
2022
|
Fortress Biotech, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
50,000
-1.25%
|
-
|
|
Oct 04
2022
|
Ernest Robert De Paolantonio Chief Financial Officer |
BUY
Open market or private sale
|
Direct |
10,093
+3.74%
|
$20,186
$2.41 P/Share
|
|
Aug 12
2022
|
Fortress Biotech, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
50,000
-1.23%
|
-
|
|
Jul 21
2022
|
Lindsay A Md Rosenwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,245
+50.0%
|
-
|
|
Jul 21
2022
|
Justin Adam Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,245
+24.35%
|
-
|
|
Jul 21
2022
|
Jeffrey Paley Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,245
+24.35%
|
-
|
|
Jul 21
2022
|
Miranda Jayne Toledano Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,245
+24.35%
|
-
|
|
Jul 21
2022
|
Claude Maraoui President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+12.04%
|
-
|
|
Jul 21
2022
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,245
+24.35%
|
-
|
|
Jul 21
2022
|
Ernest Robert De Paolantonio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+35.71%
|
-
|
|
May 12
2022
|
Fortress Biotech, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
50,000
-1.22%
|
-
|
|
Jan 14
2022
|
Ernest Robert De Paolantonio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+50.0%
|
-
|
|
Jan 14
2022
|
Justin Adam Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jan 14
2022
|
Jeffrey Paley Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jan 14
2022
|
Miranda Jayne Toledano Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jan 14
2022
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|